Provided by Tiger Trade Technology Pte. Ltd.

CytomX Therapeutics

3.21
-0.2100-6.14%
Pre-market: 3.490.2800+8.72%04:47 EDT
Volume:2.17M
Turnover:7.13M
Market Cap:698.83M
PE:-7.06
High:3.42
Open:3.40
Low:3.21
Close:3.42
52wk High:8.21
52wk Low:1.90
Shares:217.70M
Float Shares:180.00M
Volume Ratio:0.73
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4548
EPS(LYR):-0.1500
ROE:-37.75%
ROA:-19.58%
PB:2.31
PE(LYR):-21.40

Loading ...

CytomX Therapeutics, Inc.: Potential Varseta-M Monotherapy Registrational Study in R/R Mcrc Planned for Initiation in 1H 2027

THOMSON REUTERS
·
Aug 27

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug Masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R Mcrc)

THOMSON REUTERS
·
Aug 27

CytomX Therapeutics Price Target Cut to $11.00/Share from $12.00 by JP Morgan

Dow Jones
·
Aug 13

CytomX Therapeutics Price Target Cut to $14.00/Share from $15.00 by Guggenheim

Dow Jones
·
Aug 10

Barclays Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)

TIPRANKS
·
Aug 07

CytomX Q2 2026 Earnings: Revenue Falls as R&D Spending Rises

TradingKey
·
Aug 07

CytomX Q2 Revenue Misses, Partly Hurt by Lower Research Activities in the Astellas Collaboration

Reuters
·
Aug 07

CytomX Therapeutics Q2 EPS USD -0.09

THOMSON REUTERS
·
Aug 07

CytomX Therapeutics reports Q2 EPS (9c), consensus (10c)

TIPRANKS
·
Aug 07

CytomX Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

CytomX Q2 FY26 Net Loss Widens to $20.67 Million; Revenue Drops to $1.42 Million

Reuters
·
Aug 07

CytomX Therapeutics Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $1.418M Miss $12.308M Estimate

Benzinga Earnings
·
Aug 07

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 07

CytomX Therapeutics Chief Legal Officer Alejandra Carvajal Files Initial Beneficial Ownership Statement

Reuters
·
Aug 06

Press Release: CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

Dow Jones
·
Aug 03

CytomX Therapeutics Director Charles S. Fuchs Files Initial Beneficial Ownership Statement

Reuters
·
Jul 31

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

GlobeNewswire
·
Jul 30

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.d., M.p.h., to the Board of Directors

THOMSON REUTERS
·
Jul 27

Press Release: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.p.h., to the Board of Directors

Dow Jones
·
Jul 27

CytomX Therapeutics doubles authorized common shares to 600 million

Reuters
·
Jun 23